The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; Arcus Biosciences; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Agenus; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; Incendia Therapeutics; Loxo/Lilly; Macrogenics; Regeneron; Seagen; Taiho Oncology
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; Astellas Pharma; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Esteve; Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Midatech Pharma; Mirati Therapeutics (I); MSD; Pfizer (I); PharmaMar; Roche (I); Sanofi (I); Servier; Takeda
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD
 
Talia Golan
Honoraria - Abbvie; AstraZeneca/MedImmune; MSD
Consulting or Advisory Role - Abbvie; AstraZeneca
Speakers' Bureau - AstraZeneca; MSD Oncology
Research Funding - AstraZeneca (Inst); MSD (Inst)
 
Ruth Perets
Employment - Rambam Health Care Campus
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - 1E Therapeutics; GalMed Pharmacueticals; Simplivia
Research Funding - 1E Therapeutics
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Boehler Life Science Advice; BPGbio; ClearNote Health; Conjupro Biotherapeutics; Elevation Oncology; NanOlogy; Qurient; TD2; Vivacitus
Research Funding - BioNTech (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst)
 
Manuel Pedregal
No Relationships to Disclose
 
Mariano Ponz-Sarvise
Consulting or Advisory Role - AstraZeneca Spain
Travel, Accommodations, Expenses - AstraZeneca (Inst); Incyte; Oncosil
 
Mohammed Najeeb Al Hallak
Speakers' Bureau - AstraZeneca; Guardant Health; Ipsen; Seagen; Takeda
 
Shubham Pant
Consulting or Advisory Role - Alligator Bioscience; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Nihon Medi-Physics; Novartis; US WorldMeds; Zymeworks
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Valentina Boni
Employment - Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - 1TRIALSP
Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen; Loxo; MSD Oncology; Puma Biotechnology
Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Nanobiotix; Novartis; OncoArt
Speakers' Bureau - Lilly; MSD; Solti; Tactics
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Omar Saavedra
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Maria J. de Miguel
Honoraria - Janssen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - Abbvie; Array BioPharma; Eisai; Genmab; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Sanofi
 
Alexis Diane Leal
Employment - Elsevier
Leadership - Elsevier
Research Funding - Abbvie (Inst); Arrys Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conjupro Biotherapeutics (Inst); Corcept Therapeutics (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Takeda (Inst)
 
Andrés J. Muñoz Martín
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Pfizer; Celgene; Daiichi Sankyo; GlaxoSmithKline; Incyte; LEO Pharma; Lilly; MSD Oncology; Roche; Sanofi; SERVIER
Speakers' Bureau - Bayer; Menarini; Rovi; SERVIER; STADA
Research Funding - Celgene; LEO Pharma; Rovi; Sanofi
Patents, Royalties, Other Intellectual Property - Risk assessment model in venous thromboembolism in cancer patients
Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Pfizer; Roche; SERVIER
 
Tamara Sauri
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; MSD/Merck; Teva
Speakers' Bureau - Abbvie; BioLineRx; Roche
Research Funding - AstraZeneca; MSD/Merck
 
Michael Schickler
Employment - Purple Biotech
Stock and Other Ownership Interests - Purple Biotech